Omidria
Payments companies reported to CMS as associated with Omidria. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Omidria, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Omidria
These are the largest totals companies reported as associated with Omidria. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Mark Packer | Boulder, CO | Ophthalmology | $71,500.00 |
| Brian Shafer | Plymouth Meeting, PA | Cornea and External Diseases Specialist | $15,627.78 |
| David Goldman | Palm Beach Gardens, FL | Ophthalmology | $12,278.51 |
| Inder Singh | Racine, WI | Ophthalmology | $10,198.14 |
| Rebecca Metzinger | New Orleans, LA | Ophthalmology | $7,635.17 |
| Elizabeth Yeu-Lin | Norfolk, VA | Ophthalmology | $7,374.32 |
| Mark Pyfer | Jenkintown, PA | Ophthalmology | $7,232.21 |
| Sumit Garg | Irvine, CA | Cornea and External Diseases Specialist | $4,867.50 |
| Karl Stonecipher | Greensboro, NC | Ophthalmology | $4,855.18 |
| Scott Laborwit | Towson, MD | $4,777.50 |
Prescribed Omidria?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.